HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Conditions: Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Chronic Myeloid Leukemia; Myelofibrosis; Multiple Myeloma; Malignant Lymphoma Interventions: Drug: MDG1021 dose 1; Drug: MDG1021 dose 2; Drug: MDG1021 dose 3; Drug: MDG1021 optimal dose Sponsor: Medigene AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Research | Stem Cell Therapy | Stem Cells | Transplants